2755. Phase 1/2 First-in-Human Study of the Safety Tolerability and Immunogenicity of an RSV Prefusion F-Based Subunit Vaccine Candidate

摘要

BackgroundThe respiratory syncytial virus (RSV) fusion glycoprotein (F) is a molecule that fuses the viral and host cell membranes during virus entry as it rearranges from a meta-stable prefusion to a stable postfusion conformation. Using structure-guided design, Pfizer engineered a prefusion RSV F subunit vaccine antigen with stable and well-characterized conformational homogeneity.